EGFR and MET induce tumorigenesis and gefitinib resistance in lung cancers by controlling microRNA expression

Autor: Garofalo M1, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM.

Publikováno v: Nature medicine
(2011).
info:cnr-pdr/source/autori:Garofalo M1, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM./titolo:EGFR and MET induce tumorigenesis and gefitinib resistance in lung cancers by controlling microRNA expression/doi:/rivista:Nature medicine (Print)/anno:2011/pagina_da:/pagina_a:/intervallo_pagine:/volume

The involvement of the MET oncogene in de novo and acquired resistance of non-small cell lung cancers (NSCLCs) to tyrosine kinase inhibitors (TKIs) has previously been reported, but the precise mechanism by which MET overexpression contributes to TKI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::96094bcd487c8711cb718cb788079e81
http://www.cnr.it/prodotto/i/340724